SEP 08, 2020 6:46 PM PDT

The story of a very scary protein

New research from biochemists at the University of Alberta has identified a protein that triggers the growth of aggressive breast cancer cells. The discovery provides insight on how breast cancers develop, information which is crucial in advancing anticancer treatments. The findings from the study are published in the journal Cell Death and Disease.

Conducted by lead researcher Ing Swie Goping, the research pinpoints the internal mechanism of a protein called BCL-2 interacting killer (BIK), which, true to its name, can have deadly consequences. Goping had previously studied this protein in past investigations, concluding that BIK is associated with relapses in breast cancer patients.

In the most recent study, Goping continued her research in order to investigate just how BIK works its deadliness. She and her team determined that BIK triggers a failure of apoptosis – or cell death. Watch the video below to learn more about how apoptosis works in the human body.

As you can see in the video above, while normal cells (without BIK) that undergo apoptosis end up with DNA damage grave enough to kill the cell, the presence of BCL-2 interacting killer changes the conditions. With BIK present in ER-positive breast cancer cells, a cell will experience DNA damage severe enough to cause mutations but not die. This process, in turn, makes cancer cells significantly more aggressive.

"The cell that has DNA damage then manages to repair itself, and becomes a worse adversary because it has mutations," said Goping, who is a professor and a member of the Cancer Research Institute of Northern Alberta. "Those mutations give it the repertoire to do whatever it can to evade therapy or to metastasize--whatever it needs to do to survive."

Photo: Pixabay

The research team was able to demonstrate that BIK acts as a biomarker for ER-positive patients. They write: “by examining six independent cohorts of patients (total n = 969), we discovered that high BIK mRNA and protein levels predicted clinical relapse of Estrogen receptor (ER)-positive cancers, which account for almost 70% of all breast cancers diagnosed but had no predictive value for hormone receptor-negative (triple-negative) patients.”

While this news may sound glum, understanding the mechanism behind this disease actually provides new pathways for future developments in breast cancer treatments. Goping intends to further her investigations in order to continue learning about BIK’s role in patients with ER-positive breast cancer.

Sources: Cell Death and Disease, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
NOV 26, 2020
Clinical & Molecular DX
Routine Diagnostic Tests Linked to a 59 Percent Increase in Testicular Cancer Risk
NOV 26, 2020
Routine Diagnostic Tests Linked to a 59 Percent Increase in Testicular Cancer Risk
New research has revealed that exposure to radiation from diagnostic procedures such as X-rays could contribute to an el ...
NOV 26, 2020
Immunology
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
NOV 26, 2020
Armed With ImmunoBait, Red Blood Cells Fight Lung Cancers
  There’s a new weapon in the battle against lung cancer metastases: red blood cells equipped with nanopartic ...
DEC 01, 2020
Cancer
The price tag of prostate cancer treatment
DEC 01, 2020
The price tag of prostate cancer treatment
New research published in The Journal of Urology from the Official Journal of the American Urological Association&n ...
DEC 22, 2020
Cancer
No increased risk of contracting COVID-19 for head and neck cancer patients
DEC 22, 2020
No increased risk of contracting COVID-19 for head and neck cancer patients
New research published online in CANCER brings a sigh of relief for patients with head and neck cancer. The findings, pu ...
DEC 24, 2020
Cancer
Seven DNA fingerprints determine genetic predisposition for cancer
DEC 24, 2020
Seven DNA fingerprints determine genetic predisposition for cancer
New research published in Science Advances is attempting to change the way that we think about cancer. The research ...
JAN 12, 2021
Cell & Molecular Biology
Hyperactive Mitochondria Can Fuel Brain Tumors
JAN 12, 2021
Hyperactive Mitochondria Can Fuel Brain Tumors
The most common and deadly form of brain cancer is known as glioblastoma; the median survival time for patients is only ...
Loading Comments...